Journal Description
Medicina
Medicina
is an international, peer-reviewed, open access journal that covers all problems related to medicine. The journal is owned by the Lithuanian University of Health Sciences (LUHS) and is published monthly online by MDPI. Partner Societies are the Lithuanian Medical Association, Vilnius University, Rīga Stradiņš University, the University of Latvia, and the University of Tartu.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.
- Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Impact Factor:
2.4 (2023);
5-Year Impact Factor:
2.7 (2023)
Latest Articles
Multistrategic Approaches in the Treatment of Acute Migraine During Pregnancy: The Effectiveness of Physiotherapy, Exercise, and Relaxation Techniques
Medicina 2025, 61(1), 28; https://doi.org/10.3390/medicina61010028 (registering DOI) - 28 Dec 2024
Abstract
Background and Objectives: Migraine is a common neurological condition that significantly impacts quality of life, especially in women during their reproductive years. Pregnancy poses unique challenges for migraine management due to hormonal changes and the limited use of pharmacological treatments. Non-pharmacological interventions,
[...] Read more.
Background and Objectives: Migraine is a common neurological condition that significantly impacts quality of life, especially in women during their reproductive years. Pregnancy poses unique challenges for migraine management due to hormonal changes and the limited use of pharmacological treatments. Non-pharmacological interventions, such as physiotherapy, exercise, and relaxation techniques, offer promising alternatives for managing migraines during this critical period. This study aims to evaluate the effectiveness of physiotherapy, structured exercise, and relaxation techniques in reducing migraine frequency, severity, and duration while improving psychosocial outcomes such as quality of life, stress levels, and sleep quality in pregnant women. Materials and Methods: Sixty pregnant women diagnosed with acute migraine were randomly assigned into three intervention groups: physiotherapy, structured exercise, and relaxation techniques. Each intervention lasted 8 weeks. The primary outcomes included migraine frequency, severity (measured by VAS), and duration. The secondary outcomes included quality of life (SF-36), stress (PSS), and sleep quality (PSQI). Statistical analyses were conducted using one-way ANOVA and paired t-tests. Results: All interventions significantly reduced migraine frequency, severity, and duration (p < 0.05). Physiotherapy demonstrated the greatest reduction in migraine frequency (45%) and severity (36%), while exercise yielded the most significant improvement in duration (42%). Relaxation techniques were particularly effective in reducing stress and anxiety levels. Quality of life and sleep quality improved across all groups, with unique benefits observed for each intervention. Conclusions: Physiotherapy, structured exercise, and relaxation techniques are effective, safe, and non-invasive interventions for managing acute migraines during pregnancy. These findings provide evidence-based alternatives to pharmacological treatments, highlighting the importance of holistic approaches to migraine management during pregnancy. Further research is needed to confirm long-term efficacy and explore combined interventions.
Full article
(This article belongs to the Special Issue Impact of Excercise and Physical Therapy on Quality of Life in People with Migraine)
Open AccessArticle
Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
by
Julia Węgrzynek-Gallina, Tomasz Chmiela, Michał Borończyk, Aleksandra Buczek, Patrycja Hudzińska, Hubert Bigajski, Damian Waksmundzki, Justyna Gawryluk and Joanna Siuda
Medicina 2025, 61(1), 27; https://doi.org/10.3390/medicina61010027 (registering DOI) - 28 Dec 2024
Abstract
Background and Objectives: The rapid growth of the number of advanced Parkinson’s disease (PD) patients has caused a significant increase in the use of device-aided therapies (DATs), including levodopa–carbidopa intestinal gel (LCIG) and continuous subcutaneous apomorphine infusion (CSAI). The objective of this study
[...] Read more.
Background and Objectives: The rapid growth of the number of advanced Parkinson’s disease (PD) patients has caused a significant increase in the use of device-aided therapies (DATs), including levodopa–carbidopa intestinal gel (LCIG) and continuous subcutaneous apomorphine infusion (CSAI). The objective of this study was to evaluate patients’ satisfaction and the factors influencing preferences for CSAI and LCIG. Materials and Methods: The research focused on individuals diagnosed with advanced PD undergoing DAT at the Neurology Department of the University Hospital in Katowice. A telephone survey conducted between June and July 2024 evaluated the experiences of patients with LCIG and CSAI. The Parkinson’s Disease Questionnaire (PDQ-8) and the Stress Scale for Family Caregivers (BSFC-s) were applied. Based on medical record data comprising reasons for the exclusion of individuals, disease-related and treatment data were collected. Results: Among the original cohort of 64 patients, 50 completed the survey, including 31 who might choose between infusion therapies. The average patient ages were 70.6 ± 4.7 (CSAI) and 71.2 ± 7.2 years (LCIG), with disease durations of 15 (IQR: 12–19) and 18 (IQR: 13–19) years, respectively. LCIG patients presented higher PDQ-8 scores (20 (IQR:13–27) vs. 13 (IQR: 6–19), p = 0.008), and higher BSFC-s scores (19 (IQR: 12–21) vs. 9 (IQR:2,5–13), p = 0.011). Furthermore, significant factors influencing patient preferences included fear of surgery (75% vs. 36.8%, p = 0.043) and concerns about DAT safety (83.3% vs. 47.4%, p = 0.049). Conclusions: LCIG and CSAI therapies offer benefits and disadvantages, with safety concerns and fear of surgery seeming to be decisive in the decision-making process.
Full article
(This article belongs to the Section Neurology)
►▼
Show Figures
Figure 1
Open AccessArticle
The Effect of Laboratory Parameters on the Hospital Stay and Mortality in Pediatric Patients Who Underwent Lobectomy and Pneumonectomy
by
Ahmet Ulusan, Hilal Zehra Kumbasar Danaci, Bekir Elma, Maruf Sanli and Ahmet Feridun Isik
Medicina 2025, 61(1), 26; https://doi.org/10.3390/medicina61010026 (registering DOI) - 28 Dec 2024
Abstract
Background and Objectives: This study aims to evaluate the prognostic significance of various laboratory parameters in predicting the length of hospital stay and mortality among pediatric patients undergoing lobectomy and pneumonectomy for infectious or noninfectious diseases. Materials and Methods: This study was conducted
[...] Read more.
Background and Objectives: This study aims to evaluate the prognostic significance of various laboratory parameters in predicting the length of hospital stay and mortality among pediatric patients undergoing lobectomy and pneumonectomy for infectious or noninfectious diseases. Materials and Methods: This study was conducted by retrospective data analysis of 59 pediatric patients who underwent lobectomy and pneumonectomy due to variable diseases at the department of chest surgery. Pediatric patients diagnosed with variable diseases and who underwent lobectomy or pneumonectomy, patients who were hospitalized during the study period and underwent surgical intervention, and patients who had at least one laboratory parameter recorded before surgery were included in the study. Laboratory parameters included white blood cell (WBC) count, red cell distribution width (RDW), platelet (PLT) count, neutrophil count, mean platelet volume (MPV), monocyte count and lymphocyte count. Laboratory results were obtained from the patients’ most recent blood samples before surgery. In addition, derived ratios such as platelet-to-lymphocyte ratio (PLR), MPV-to-PLT ratio (MPR), MPV-to-monocyte ratio (MMR), MPV-to-lymphocyte ratio (MPVLR), monocyte-to-lymphocyte ratio (MLR) and neutrophil-to-lymphocyte ratio (NLR), and Pan-Immune-Inflammation Value (PIV) were calculated and their potential prognostic values were evaluated. Results: The mean age of the patients was 6.3 years (0–15 years). The gender distribution of the patients in the study group was determined as 36 male patients (61%) and 23 female patients (39%). Lobectomy was the most commonly performed surgical procedure, accounting for 83% of cases, while pneumonectomy was applied in 17% of cases. The postoperative complication rate was observed as 34%. The mean hospital stay of the patients was calculated as 12.61 days (2–84 days), while the mortality rate was recorded as 8.5%. The relationship between the neutrophil count and the length of hospital stay is quite strong, and the r value was calculated as 0.550 (p < 0.01). PIV showed a strong correlation with length of hospital stay, with an r value of 0.650 (p < 0.01). A significant relationship was also found between PLR and length of hospital stay (r = 0.500, p < 0.01). The parameters with the highest positive effect on the hospital stay are neutrophil count (B = 0.400, p < 0.01) and PIV (B = 0.500, p < 0.01). The mean hospital stay was 10.00 days (2–30) in patients without complications and 15.00 days (5–40) in patients with complications, and this difference was also significant (p < 0.01). Finally, the mortality rate was 2.5% in patients without complications, while it was determined as 20% in those with complications (p < 0.01). Conclusions: This study determines the effects of laboratory parameters (particularly PIV, neutrophil, PLR, and NLR) on the duration of hospital stay, development of complications, and mortality and emphasizes the importance of monitoring these parameters in the treatment of infectious or noninfectious diseases.
Full article
(This article belongs to the Section Pulmonology)
►▼
Show Figures
Figure 1
Open AccessSystematic Review
Safety and Potential Complications of Facial Wrinkle Correction with Dermal Fillers: A Systematic Literature Review
by
Audra Janovskiene, Deividas Chomicius, Dominykas Afanasjevas, Zygimantas Petronis, Dainius Razukevicius and Egle Jagelaviciene
Medicina 2025, 61(1), 25; https://doi.org/10.3390/medicina61010025 (registering DOI) - 27 Dec 2024
Abstract
Background and Objectives: The history of facial fillers is very broad, ranging from the use of various materials to modern technologies. Although procedures are considered safe, complications such as skin inflammation, infection, necrosis, or swelling may occur. It is crucial for specialists
[...] Read more.
Background and Objectives: The history of facial fillers is very broad, ranging from the use of various materials to modern technologies. Although procedures are considered safe, complications such as skin inflammation, infection, necrosis, or swelling may occur. It is crucial for specialists to be adequately prepared, inform patients how to prepare for corrective procedures, adhere to high safety standards, and continually educate. The goal of this systematic review is to identify complications arising during facial wrinkle correction procedures, as well as to explore safety and potential prevention strategies. Materials and methods: The review of the scientific literature followed the PRISMA guidelines. The search was performed in a single scientific database: PubMed. Considering predefined inclusion and exclusion criteria, articles evaluating the safety of dermal fillers used for facial wrinkle correction, complications, and treatment outcomes were selected. The chosen articles were published from 15 February 2019 to 15 February 2024 (last search date: 25 February 2024). The selected articles compared the complications, product safety, and result longevity of various dermal fillers used for facial wrinkle correction. Results: In thirty-eight articles, which involved 3967 participants, a total of 8795 complications were reported. The majority of complications occurred after injections into the chin and surrounding area (n = 2852). Others were reported in lips and the surrounding area (n = 1911) and cheeks and the surrounding area (n = 1077). Out of the 8795 complications, 1076 were adverse events (AE), including two severe AE cases: mild skin necrosis (n = 1) and abscess (n = 1). There were no cases of vascular occlusion, visual impairment, or deaths related to the performed procedures. A total of 7719 injection site reactions were classified as mild or temporary, such as swelling (n = 1184), sensitivity (n = 1145), pain (n = 1064), bleeding (n = 969), hardening/stiffness (n = 888), nodules/irregularities (n = 849), and erythema (redness) (n = 785). Conclusions: Facial wrinkle correction procedures are generally safe and effective and the results can last from 6 to 24 months, depending on the dermal filler material and its components used. The most common complications after dermal filler injection usually resolve spontaneously, but if they persist, various pharmacological treatment methods can be used according to the condition, and surgical intervention is generally not required.
Full article
(This article belongs to the Section Dentistry and Oral Health)
►▼
Show Figures
Figure 1
Figure 1
<p>Systematic review article search process diagram.</p> Full article ">Figure 2
<p>Systematic risk assessment of non−randomized clinical trials [<a href="#B20-medicina-61-00025" class="html-bibr">20</a>,<a href="#B21-medicina-61-00025" class="html-bibr">21</a>,<a href="#B24-medicina-61-00025" class="html-bibr">24</a>,<a href="#B26-medicina-61-00025" class="html-bibr">26</a>,<a href="#B36-medicina-61-00025" class="html-bibr">36</a>,<a href="#B50-medicina-61-00025" class="html-bibr">50</a>].</p> Full article ">Figure 3
<p>Assessment of Systematic Risk in Randomized Controlled Trials, refs. [<a href="#B14-medicina-61-00025" class="html-bibr">14</a>,<a href="#B15-medicina-61-00025" class="html-bibr">15</a>,<a href="#B16-medicina-61-00025" class="html-bibr">16</a>,<a href="#B17-medicina-61-00025" class="html-bibr">17</a>,<a href="#B18-medicina-61-00025" class="html-bibr">18</a>,<a href="#B19-medicina-61-00025" class="html-bibr">19</a>,<a href="#B22-medicina-61-00025" class="html-bibr">22</a>,<a href="#B23-medicina-61-00025" class="html-bibr">23</a>,<a href="#B24-medicina-61-00025" class="html-bibr">24</a>,<a href="#B25-medicina-61-00025" class="html-bibr">25</a>,<a href="#B27-medicina-61-00025" class="html-bibr">27</a>,<a href="#B28-medicina-61-00025" class="html-bibr">28</a>,<a href="#B29-medicina-61-00025" class="html-bibr">29</a>,<a href="#B30-medicina-61-00025" class="html-bibr">30</a>,<a href="#B31-medicina-61-00025" class="html-bibr">31</a>,<a href="#B32-medicina-61-00025" class="html-bibr">32</a>,<a href="#B33-medicina-61-00025" class="html-bibr">33</a>,<a href="#B34-medicina-61-00025" class="html-bibr">34</a>,<a href="#B35-medicina-61-00025" class="html-bibr">35</a>,<a href="#B38-medicina-61-00025" class="html-bibr">38</a>,<a href="#B39-medicina-61-00025" class="html-bibr">39</a>,<a href="#B40-medicina-61-00025" class="html-bibr">40</a>,<a href="#B41-medicina-61-00025" class="html-bibr">41</a>,<a href="#B42-medicina-61-00025" class="html-bibr">42</a>,<a href="#B43-medicina-61-00025" class="html-bibr">43</a>,<a href="#B44-medicina-61-00025" class="html-bibr">44</a>,<a href="#B45-medicina-61-00025" class="html-bibr">45</a>,<a href="#B46-medicina-61-00025" class="html-bibr">46</a>,<a href="#B47-medicina-61-00025" class="html-bibr">47</a>,<a href="#B48-medicina-61-00025" class="html-bibr">48</a>,<a href="#B49-medicina-61-00025" class="html-bibr">49</a>,<a href="#B51-medicina-61-00025" class="html-bibr">51</a>].</p> Full article ">
<p>Systematic review article search process diagram.</p> Full article ">Figure 2
<p>Systematic risk assessment of non−randomized clinical trials [<a href="#B20-medicina-61-00025" class="html-bibr">20</a>,<a href="#B21-medicina-61-00025" class="html-bibr">21</a>,<a href="#B24-medicina-61-00025" class="html-bibr">24</a>,<a href="#B26-medicina-61-00025" class="html-bibr">26</a>,<a href="#B36-medicina-61-00025" class="html-bibr">36</a>,<a href="#B50-medicina-61-00025" class="html-bibr">50</a>].</p> Full article ">Figure 3
<p>Assessment of Systematic Risk in Randomized Controlled Trials, refs. [<a href="#B14-medicina-61-00025" class="html-bibr">14</a>,<a href="#B15-medicina-61-00025" class="html-bibr">15</a>,<a href="#B16-medicina-61-00025" class="html-bibr">16</a>,<a href="#B17-medicina-61-00025" class="html-bibr">17</a>,<a href="#B18-medicina-61-00025" class="html-bibr">18</a>,<a href="#B19-medicina-61-00025" class="html-bibr">19</a>,<a href="#B22-medicina-61-00025" class="html-bibr">22</a>,<a href="#B23-medicina-61-00025" class="html-bibr">23</a>,<a href="#B24-medicina-61-00025" class="html-bibr">24</a>,<a href="#B25-medicina-61-00025" class="html-bibr">25</a>,<a href="#B27-medicina-61-00025" class="html-bibr">27</a>,<a href="#B28-medicina-61-00025" class="html-bibr">28</a>,<a href="#B29-medicina-61-00025" class="html-bibr">29</a>,<a href="#B30-medicina-61-00025" class="html-bibr">30</a>,<a href="#B31-medicina-61-00025" class="html-bibr">31</a>,<a href="#B32-medicina-61-00025" class="html-bibr">32</a>,<a href="#B33-medicina-61-00025" class="html-bibr">33</a>,<a href="#B34-medicina-61-00025" class="html-bibr">34</a>,<a href="#B35-medicina-61-00025" class="html-bibr">35</a>,<a href="#B38-medicina-61-00025" class="html-bibr">38</a>,<a href="#B39-medicina-61-00025" class="html-bibr">39</a>,<a href="#B40-medicina-61-00025" class="html-bibr">40</a>,<a href="#B41-medicina-61-00025" class="html-bibr">41</a>,<a href="#B42-medicina-61-00025" class="html-bibr">42</a>,<a href="#B43-medicina-61-00025" class="html-bibr">43</a>,<a href="#B44-medicina-61-00025" class="html-bibr">44</a>,<a href="#B45-medicina-61-00025" class="html-bibr">45</a>,<a href="#B46-medicina-61-00025" class="html-bibr">46</a>,<a href="#B47-medicina-61-00025" class="html-bibr">47</a>,<a href="#B48-medicina-61-00025" class="html-bibr">48</a>,<a href="#B49-medicina-61-00025" class="html-bibr">49</a>,<a href="#B51-medicina-61-00025" class="html-bibr">51</a>].</p> Full article ">
Open AccessReview
Emerging Strategies in Cartilage Repair and Joint Preservation
by
Mircea Adrian Focsa, Sorin Florescu and Armand Gogulescu
Medicina 2025, 61(1), 24; https://doi.org/10.3390/medicina61010024 - 27 Dec 2024
Abstract
Background and Objectives: Cartilage repair remains a critical challenge in orthopaedic medicine due to the tissue’s limited self-healing ability, contributing to degenerative joint conditions such as osteoarthritis (OA). In response, regenerative medicine has developed advanced therapeutic strategies, including cell-based therapies, gene editing, and
[...] Read more.
Background and Objectives: Cartilage repair remains a critical challenge in orthopaedic medicine due to the tissue’s limited self-healing ability, contributing to degenerative joint conditions such as osteoarthritis (OA). In response, regenerative medicine has developed advanced therapeutic strategies, including cell-based therapies, gene editing, and bioengineered scaffolds, to promote cartilage regeneration and restore joint function. This narrative review aims to explore the latest developments in cartilage repair techniques, focusing on mesenchymal stem cell (MSC) therapy, gene-based interventions, and biomaterial innovations. It also discusses the impact of patient-specific factors, such as age, defect size, and cost efficiency, on treatment selection and outcomes. Materials and Methods: This review synthesises findings from recent clinical and preclinical studies published within the last five years, retrieved from the PubMed, Scopus, and Web of Science databases. The search targeted key terms such as “cartilage repair”, “stem cell therapy”, “gene editing”, “biomaterials”, and “tissue engineering”. Results: Advances in MSC-based therapies, including autologous chondrocyte implantation (ACI) and platelet-rich plasma (PRP), have demonstrated promising regenerative potential. Gene-editing tools like CRISPR/Cas9 have facilitated targeted cellular modifications, while novel biomaterials such as hydrogels, biodegradable scaffolds, and 3D-printed constructs have improved mechanical support and tissue integration. Additionally, biophysical stimuli like low-intensity pulsed ultrasound (LIPUS) and electromagnetic fields (EMFs) have enhanced chondrogenic differentiation and matrix production. Treatment decisions are influenced by patient age, cartilage defect size, and financial considerations, highlighting the need for personalised and multimodal approaches. Conclusions: Combining regenerative techniques, including cell-based therapies, gene modifications, and advanced scaffolding, offers a promising pathway towards durable cartilage repair and joint preservation. Future research should focus on refining integrated therapeutic protocols, conducting long-term clinical evaluations, and embracing personalised treatment models driven by artificial intelligence and predictive algorithms.
Full article
(This article belongs to the Section Orthopedics)
Open AccessArticle
Pelvic Floor Muscle Training vs. Vaginal Vibration Cone Therapy for Postpartum Dyspareunia and Vaginal Laxity
by
Federico Villani, Izabella Petre, Florina Buleu, Stela Iurciuc, Luciana Marc, Adrian Apostol, Chiara Valentini, Elisabetta Donati, Tommaso Simoncini, Ion Petre and Cristian Furau
Medicina 2025, 61(1), 23; https://doi.org/10.3390/medicina61010023 - 27 Dec 2024
Abstract
Background and Objectives: Pelvic floor dysfunction and sexual health issues are common postpartum due to weakened pelvic muscles, significantly impacting women’s quality of life (QoL). Pelvic floor muscle training (PFMT) is a widely used approach to address these issues. This study aimed to
[...] Read more.
Background and Objectives: Pelvic floor dysfunction and sexual health issues are common postpartum due to weakened pelvic muscles, significantly impacting women’s quality of life (QoL). Pelvic floor muscle training (PFMT) is a widely used approach to address these issues. This study aimed to compare the effectiveness of two rehabilitation methods—vibrating vaginal cones (VCG) and PFMT exercises (CG)—in improving pelvic floor muscle strength, reducing dyspareunia, and enhancing sexual function in postpartum women. Materials and Methods: This 1-year retrospective observational analysis evaluated 57 postpartum women presenting with perineal muscle relaxation and sexual dysfunction. Participants were assessed 3 months postpartum (T0) and after 3 months of therapy (T1) at the Pelvic Floor Rehabilitation Clinic of Santa Chiara Hospital, Pisa. Outcomes were measured using the pubococcygeus (PC) test for pelvic floor strength and the Female Sexual Function Index (FSFI) for sexual function. Results: The results revealed significant improvements in pelvic floor muscle strength and sexual function across both groups. While both interventions effectively reduced dyspareunia, the VCG group demonstrated superior outcomes, with 96.67% of participants reporting no pain compared to 80.95% in the CG. FSFI scores improved significantly in both groups, with greater enhancements in arousal, desire, and pain domains observed in the VCG group (p < 0.01). Vaginal cone therapy also resulted in slightly higher gains in overall pelvic floor strength. Conclusions: These findings suggest that vibrating vaginal cones may be a promising option for postpartum pelvic floor rehabilitation, with potential benefits for improving sexual satisfaction and reducing pain.
Full article
(This article belongs to the Special Issue New Advances in Female Pelvic Floor Dysfunctions Management: 2nd Edition)
►▼
Show Figures
Figure 1
Figure 1
<p>Distribution of dyspareunia by groups, at T0: (<b>a</b>)-CG, (<b>b</b>)-VCG.</p> Full article ">Figure 2
<p>Distribution of dyspareunia by groups, at T1: (<b>a</b>)-CG, (<b>b</b>)-VCG.</p> Full article ">Figure 3
<p>PC test score distribution by groups: (<b>a</b>) at T0, (<b>b</b>) at T1.</p> Full article ">Figure 4
<p>FSFI score distribution by groups: (<b>a</b>) at T0, (<b>b</b>) at T1.</p> Full article ">
<p>Distribution of dyspareunia by groups, at T0: (<b>a</b>)-CG, (<b>b</b>)-VCG.</p> Full article ">Figure 2
<p>Distribution of dyspareunia by groups, at T1: (<b>a</b>)-CG, (<b>b</b>)-VCG.</p> Full article ">Figure 3
<p>PC test score distribution by groups: (<b>a</b>) at T0, (<b>b</b>) at T1.</p> Full article ">Figure 4
<p>FSFI score distribution by groups: (<b>a</b>) at T0, (<b>b</b>) at T1.</p> Full article ">
Open AccessArticle
The Impact of Pelvic Floor Muscle Strengthening on the Functional State of Women Who Have Experienced OASIS After Childbirth
by
Atėnė Simanauskaitė, Justina Kačerauskienė, Dalia Regina Railaitė and Eglė Bartusevičienė
Medicina 2025, 61(1), 22; https://doi.org/10.3390/medicina61010022 - 27 Dec 2024
Abstract
Background and Objectives: The primary objective of this study was to assess the impact of pelvic floor muscle (PFM) strengthening on the pelvic floor function in women who have experienced OASIS two years after delivery, and the secondary objective was to educate women
[...] Read more.
Background and Objectives: The primary objective of this study was to assess the impact of pelvic floor muscle (PFM) strengthening on the pelvic floor function in women who have experienced OASIS two years after delivery, and the secondary objective was to educate women about PFM strengthening and instruct them on the correct way to exercise. Methods and Materials: A prospective case-control study was conducted. The participants were divided into two groups: the case group (women who experienced OASIS) and the control group (women who did not experience perineal tears but had similar obstetric-related data to the case). Women were invited for a gynecological exam, PFM assessment, and consultation on PFM training. Women in the case group had three consultations, and women in the control group had two. Women were presented with four sets of questions about pre-pregnancy condition and questions related to UI and FI after delivery. Results were considered significant when p < 0.05. Results: OASIS were detected in 13 (0.4%) women in 2021. Risk factors for OASIS were found to be fetal macrosomia (p = 0.012), fetal occiput posterior position (p = 0.001), and epidural analgesia (p = 0.003). After one year of performing PFM strengthening exercises, some women in the study group exhibited stronger PFM contractions (p = 0.076), while others held the contracted PFM for a longer time (p = 0.133). UI affected women in the control group more often (p = 0.019). Two years after delivery, gas incontinence was mentioned significantly more frequently in the case group (p = 0.019). One year after initial consultation, gas incontinence was also more significantly common in the case group (p = 0.037). Conclusions: This study found that PFM strengthening exercises significantly improved pelvic floor function in women who experienced OASIS two years after delivery. Participants exhibited stronger PFM contractions and an increased ability to maintain these contractions. Women reported a better understanding of PFM exercises and proper techniques.
Full article
(This article belongs to the Special Issue New Advances in Female Pelvic Floor Dysfunctions Management: 2nd Edition)
►▼
Show Figures
Figure 1
Open AccessReview
The Impact of the Metabolic Syndrome Severity on the Appearance of Primary and Permanent DNA Damage
by
Mirta Milić, Luka Kazensky and Martina Matovinović
Medicina 2025, 61(1), 21; https://doi.org/10.3390/medicina61010021 - 27 Dec 2024
Abstract
The prevalence of metabolic syndrome (MetS) worldwide is rapid and significant on a global scale. A 2022 meta-analysis of data from 28 million individuals revealed a global prevalence of 45.1%, with notably higher rates in the Eastern Mediterranean Region and the Americas, particularly
[...] Read more.
The prevalence of metabolic syndrome (MetS) worldwide is rapid and significant on a global scale. A 2022 meta-analysis of data from 28 million individuals revealed a global prevalence of 45.1%, with notably higher rates in the Eastern Mediterranean Region and the Americas, particularly in high-income countries. MetS is associated with impaired antioxidant defense mechanisms, resulting in the excessive generation of reactive oxygen and nitrogen species (RONS) and elevated levels of DNA damage. Unrepaired damage can lead to DNA base changes, chromosomal mutations, genomic loss and instability, and disrupted gene and protein expression. Such changes contribute to an increased risk of tumorigenesis, cancer progression, and mortality. The alkaline comet and micronucleus cytome assay are commonly used assays for DNA damage evaluation. The estimation of damage with those two techniques demonstrated the link between the increased risk of cancer and mortality. Incorporating these techniques in a set of biomarkers to assess the MetS severity holds promise; however, comprehensive literature reviews featuring large-scale studies integrating both assays remain scarce. This systematic review aims to integrate and critically evaluate the existing scientific literature regarding this topic.
Full article
(This article belongs to the Special Issue Dyslipidemia, Obesity and Metabolic Dysfunction-Associated Fatty Liver Disease: From Roots to Management)
►▼
Show Figures
Figure 1
Figure 1
<p>(<b>a</b>)—Photomicrographs of the cells scored in the CBMN cytome assay stained with Giemsa, 1000× magnification: (<b>A</b>) mononucleated cell, (<b>B</b>) binucleated (BN) cell, (<b>C</b>) trinucleated cell, (<b>D</b>) tetranucleated cell, (<b>E</b>) BN cell with MN, (<b>F</b>) BN cell with two MNs, and (<b>G</b>) BN cell with nuclear bud (NBUD). NBUD represents gene amplification, (<b>H</b>) BN cell with two NBUDs, and (<b>I</b>) BN cell with nucleoplasmic bridge (NPB). NPB represents bicentric chromosome; (<b>b</b>)—different types of damaged (with tail) and non-damaged cells (without the tail) in the alkaline comet, with different filters only for imaging purposes, 400× magnification, captured with Metafer semi-automated microscope for slides and picture analysis.</p> Full article ">Figure 2
<p>PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases and registers only.</p> Full article ">Figure 3
<p>Link between metabolic syndrome and markers of CBMN, the comet assay, and its modifications (picture modified from Franzke et al., 2020 [<a href="#B31-medicina-61-00021" class="html-bibr">31</a>], and our findings [<a href="#B26-medicina-61-00021" class="html-bibr">26</a>]).</p> Full article ">
<p>(<b>a</b>)—Photomicrographs of the cells scored in the CBMN cytome assay stained with Giemsa, 1000× magnification: (<b>A</b>) mononucleated cell, (<b>B</b>) binucleated (BN) cell, (<b>C</b>) trinucleated cell, (<b>D</b>) tetranucleated cell, (<b>E</b>) BN cell with MN, (<b>F</b>) BN cell with two MNs, and (<b>G</b>) BN cell with nuclear bud (NBUD). NBUD represents gene amplification, (<b>H</b>) BN cell with two NBUDs, and (<b>I</b>) BN cell with nucleoplasmic bridge (NPB). NPB represents bicentric chromosome; (<b>b</b>)—different types of damaged (with tail) and non-damaged cells (without the tail) in the alkaline comet, with different filters only for imaging purposes, 400× magnification, captured with Metafer semi-automated microscope for slides and picture analysis.</p> Full article ">Figure 2
<p>PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases and registers only.</p> Full article ">Figure 3
<p>Link between metabolic syndrome and markers of CBMN, the comet assay, and its modifications (picture modified from Franzke et al., 2020 [<a href="#B31-medicina-61-00021" class="html-bibr">31</a>], and our findings [<a href="#B26-medicina-61-00021" class="html-bibr">26</a>]).</p> Full article ">
Open AccessReview
Challenges and Innovations in Alveolar Bone Regeneration: A Narrative Review on Materials, Techniques, Clinical Outcomes, and Future Directions
by
Diana Marian, Giuseppe Toro, Giovanbattista D’Amico, Maria Consiglia Trotta, Michele D’Amico, Alexandru Petre, Ioana Lile, Anca Hermenean and Anca Fratila
Medicina 2025, 61(1), 20; https://doi.org/10.3390/medicina61010020 - 27 Dec 2024
Abstract
This review explores the recent advancements and ongoing challenges in regenerating alveolar bone, which is essential for dental implants and periodontal health. It examines traditional techniques like guided bone regeneration and bone grafting, alongside newer methods such as stem cell therapy, gene therapy,
[...] Read more.
This review explores the recent advancements and ongoing challenges in regenerating alveolar bone, which is essential for dental implants and periodontal health. It examines traditional techniques like guided bone regeneration and bone grafting, alongside newer methods such as stem cell therapy, gene therapy, and 3D bioprinting. Each approach is considered for its strengths in supporting bone growth and integration, especially in cases where complex bone defects make regeneration difficult. This review also looks at different biomaterials, from bioactive scaffolds to nanomaterials, assessing how well they encourage cell growth and healing. Personalized treatments, like customized 3D-printed scaffolds, show promise in enhancing bone formation and tissue compatibility. Additionally, signaling molecules, like bone morphogenetic proteins, play a crucial role in guiding the process of bone formation and remodeling. Despite these advances, challenges remain—particularly with severe bone loss and with refining biomaterials for more reliable, long-term outcomes. This review proposes combining advanced materials, regenerative technologies, and personalized approaches to achieve more effective and consistent outcomes in oral and maxillofacial surgery.
Full article
(This article belongs to the Special Issue Medicine and Dentistry: New Methods and Clinical Approaches—2nd Edition)
►▼
Show Figures
Figure 1
Open AccessReview
Multimodal Screening for Pulmonary Arterial Hypertension in Systemic Scleroderma: Current Methods and Future Directions
by
Ioan-Teodor Dragoi, Ciprian Rezus, Alexandra Maria Burlui, Ioana Bratoiu and Elena Rezus
Medicina 2025, 61(1), 19; https://doi.org/10.3390/medicina61010019 - 27 Dec 2024
Abstract
Systemic sclerosis (SSc) is an immuno-inflammatory rheumatic disease that can affect both the skin and internal organs through fibrosis. Pulmonary arterial hypertension (PAH) is one of the most severe secondary complications. Structural changes in the vascular bed lead to increased pressures in the
[...] Read more.
Systemic sclerosis (SSc) is an immuno-inflammatory rheumatic disease that can affect both the skin and internal organs through fibrosis. Pulmonary arterial hypertension (PAH) is one of the most severe secondary complications. Structural changes in the vascular bed lead to increased pressures in the pulmonary circulation, severely impacting the right heart and significantly affecting mortality. The gold standard for diagnosing PAH is right heart catheterization (RHC), an invasive method for measuring cardiac pressure. Due to the high risk of complications, procedural difficulties, and significant costs, non-invasive screening for SSc-PAH has garnered significant interest. Echocardiography is likely the most important screening tool, providing structural and functional information about the right heart through measurements that have proven their utility over time. In addition to imagistic investigations, serum biomarkers aid in identifying patients at risk for PAH and can provide prognostic information. Currently, well-known serum biomarkers (NT-proBNP, uric acid) are used in screening; however, in recent years, researchers have highlighted new biomarkers that can enhance diagnostic accuracy for SSc patients. Pulmonary involvement can also be assessed through pulmonary function tests, which, using established thresholds, can provide additional information and help select patients requiring RHC. In conclusion, given the invasiveness of RHC, non-invasive screening methods are particularly important for SSc patients.
Full article
(This article belongs to the Section Hematology and Immunology)
Open AccessArticle
Development of a Predictive Model of Occult Cancer After a Venous Thromboembolism Event Using Machine Learning: The CLOVER Study
by
Anabel Franco-Moreno, Elena Madroñal-Cerezo, Cristina Lucía de Ancos-Aracil, Ana Isabel Farfán-Sedano, Nuria Muñoz-Rivas, José Bascuñana Morejón-Girón, José Manuel Ruiz-Giardín, Federico Álvarez-Rodríguez, Jesús Prada-Alonso, Yvonne Gala-García, Miguel Ángel Casado-Suela, Ana Bustamante-Fermosel, Nuria Alfaro-Fernández and Juan Torres-Macho
Medicina 2025, 61(1), 18; https://doi.org/10.3390/medicina61010018 - 27 Dec 2024
Abstract
Background and Objectives: Venous thromboembolism (VTE) can be the first manifestation of an underlying cancer. This study aimed to develop a predictive model to assess the risk of occult cancer between 30 days and 24 months after a venous thrombotic event using
[...] Read more.
Background and Objectives: Venous thromboembolism (VTE) can be the first manifestation of an underlying cancer. This study aimed to develop a predictive model to assess the risk of occult cancer between 30 days and 24 months after a venous thrombotic event using machine learning (ML). Materials and Methods: We designed a case–control study nested in a cohort of patients with VTE included in a prospective registry from two Spanish hospitals between 2005 and 2021. Both clinically and ML-driven feature selection were performed to identify predictors for occult cancer. XGBoost, LightGBM, and CatBoost algorithms were used to train different prediction models, which were subsequently validated in a hold-out dataset. Results: A total of 815 patients with VTE were included (51.5% male and median age of 59). During follow-up, 56 patients (6.9%) were diagnosed with cancer. One hundred and twenty-one variables were explored for the predictive analysis. CatBoost obtained better performance metrics among the ML models analyzed. The final CatBoost model included, among the top 15 variables to predict hidden malignancy, age, gender, systolic blood pressure, heart rate, weight, chronic lung disease, D-dimer, alanine aminotransferase, hemoglobin, serum creatinine, cholesterol, platelets, triglycerides, leukocyte count and previous VTE. The model had an ROC-AUC of 0.86 (95% CI, 0.83–0.87) in the test set. Sensitivity, specificity, and negative and positive predictive values were 62%, 94%, 93% and 75%, respectively. Conclusions: This is the first risk score developed for identifying patients with VTE who are at increased risk of occult cancer using ML tools, obtaining a remarkably high diagnostic accuracy. This study’s limitations include potential information bias from electronic health records and a small cancer sample size. In addition, variability in detection protocols and evolving clinical practices may affect model accuracy. Our score needs external validation.
Full article
(This article belongs to the Section Oncology)
►▼
Show Figures
Figure 1
Figure 1
<p>Machine learning pipeline. Abbreviations: PPV, positive predictive value; NPV, negative predictive value; ROC-AUC, area under the receiver operating characteristic curve.</p> Full article ">Figure 2
<p>Flowchart of patients. Abbreviations: VTE, venous thromboembolism.</p> Full article ">Figure 3
<p>ROC-AUC of the final model according to the test set.</p> Full article ">Figure 4
<p>Confusion matrix of the final CatBoost model in the test set.</p> Full article ">
<p>Machine learning pipeline. Abbreviations: PPV, positive predictive value; NPV, negative predictive value; ROC-AUC, area under the receiver operating characteristic curve.</p> Full article ">Figure 2
<p>Flowchart of patients. Abbreviations: VTE, venous thromboembolism.</p> Full article ">Figure 3
<p>ROC-AUC of the final model according to the test set.</p> Full article ">Figure 4
<p>Confusion matrix of the final CatBoost model in the test set.</p> Full article ">
Open AccessReview
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by
Chenqi Lu, Cong Xu and Jun Yang
Medicina 2025, 61(1), 17; https://doi.org/10.3390/medicina61010017 - 26 Dec 2024
Abstract
As an incretin hormone, Glucagon-like peptide-1 (GLP-1) has obvious effects on blood glucose regulation and weight loss. GLP-1 receptor (GLP-1R) agonists are synthetic products that have similar effects to GLP-1 but are less prone to degradation, and they are widely used in the
[...] Read more.
As an incretin hormone, Glucagon-like peptide-1 (GLP-1) has obvious effects on blood glucose regulation and weight loss. GLP-1 receptor (GLP-1R) agonists are synthetic products that have similar effects to GLP-1 but are less prone to degradation, and they are widely used in the treatment of type 2 diabetes and obesity. In recent years, different beneficial effects of GLP-1R agonists were discovered, such as reducing ischemia-reperfusion injury, improving the function of various organs, alleviating substance use disorder, affecting tumorigenesis, regulating bone metabolism, changing gut microbiota composition, and prolonging graft survival. Therefore, GLP-1R agonists have great potential for clinical application in various diseases. Here, we briefly summarized the beneficial effects of GLP-1R agonists other than the anti-diabetic and anti-obesity effects.
Full article
(This article belongs to the Section Endocrinology)
►▼
Show Figures
Figure 1
Figure 1
<p>Possible mechanisms of action of GLP-1 receptor agonists. (<b>A</b>) The GLP-1 receptor (GLP-1R) is a 7-fold transmembrane G protein-coupled receptor (GPCR), which can identify GLP-1 and its analogs. GLP-1R agonists can bind to GLP-1R to form a complex, which in turn activates the G protein linked to the receptor by binding it to GTP. Then, the activated G protein activates the adenylyl cyclase (AC), which in turn catalyzes the production of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). Following an increase in cAMP levels, some proteins are activated, including protein kinase A (PKA), the Exchange Protein Activated by cAMP (EPAC), the Popeye Domain Containing (POPDC) protein family, and so on. After activation, these proteins perform a range of functions. They can exert effects on ion channels, such as promoting calcium (Ca<sup>2+</sup>) channel opening and potassium (K+) channel closing, and they will also catalyze the phosphorylation of corresponding downstream proteins, resulting in multiple biological effects. After exposure to GLP-1 and its analogs, GLP-1R undergoes endocytosis and accumulates in the endosomal compartments. Then, the ligand is proteolyzed by endosomal acidification, and the GLP-1R is recycled to the membrane. After these three processes, GLP-1R is desensitized and can be reactivated [<a href="#B35-medicina-61-00017" class="html-bibr">35</a>]. (<b>B</b>) GLP-1 (1-37) is cleaved to produce GLP-1 (7-36), which is the active form of GLP-1. With the action of dipeptidyl peptidase (DPP-4), GLP-1 (7-36) is cleaved to GLP-1 (9-36) and can be further cleaved to GLP-1 (28-36) in response to neutral endopeptidase (NEP). GLP-1 (9-36) and GLP-1 (28-36) are the metabolites of GLP-1, which have a very low affinity for GLP-1R. They can bind to other receptors (which are still unclear), on the one hand, to activate downstream protein kinases, such as MAPK, PI3K, etc., and on the other hand, to be internalized and cleaved to many small peptides which can affect mitochondrial function. GLP-1R is not involved in these processes [<a href="#B24-medicina-61-00017" class="html-bibr">24</a>,<a href="#B31-medicina-61-00017" class="html-bibr">31</a>]. (<b>C</b>) In addition to GLP-1R, GLP-1R agonists may also bind to some receptors which share homology with GLP-1R, such as the glucagon receptor superfamily, insulin receptor, glucose-dependent insulinotropic peptide (GIP) receptor, insulin-like growth factor 1 (IGR-1) receptor, and so on. After binding GLP-1R agonists to these receptors, downstream protein kinases such as MAPK, PI3K, etc., are activated, and this effect is not blocked by exendin 9-39, which is a GLP-1R antagonist [<a href="#B24-medicina-61-00017" class="html-bibr">24</a>]. (<b>D</b>) Peripheral GLP-1R agonists can interact with sensory afferent neurons, through which nerve impulses are transmitted to the nucleus tractus solitaries (NTS) and activate neurons in it, and then upward to the hypothalamus. After the information is integrated, the hypothalamus sends out descending impulses, which may activate the vagal motor neurons. The activated vagal motor neurons can send stimulatory or inhibitory impulses to various organs, thereby regulating organ function. For example, they can promote pancreatic secretory function and inhibit gastrointestinal motility and gastrin release. These effects, which involve afferent vagus signaling, are not blocked by exendin 9-39 [<a href="#B25-medicina-61-00017" class="html-bibr">25</a>]. This figure was created at <a href="https://BioRender.com" target="_blank">https://BioRender.com</a>.</p> Full article ">Figure 2
<p>Beneficial effects of GLP-1 receptor agonists on PCOS (created in <a href="https://BioRender.com" target="_blank">https://BioRender.com</a>).</p> Full article ">Figure 3
<p>Biological effects of GLP-1 receptor agonists (created in <a href="https://BioRender.com" target="_blank">https://BioRender.com</a>). ↓ indicates the ability to alleviate disease damage or exert an inhibitory effect; ↑ indicates the ability to promote disease progression or exert a stimulatory effect.</p> Full article ">
<p>Possible mechanisms of action of GLP-1 receptor agonists. (<b>A</b>) The GLP-1 receptor (GLP-1R) is a 7-fold transmembrane G protein-coupled receptor (GPCR), which can identify GLP-1 and its analogs. GLP-1R agonists can bind to GLP-1R to form a complex, which in turn activates the G protein linked to the receptor by binding it to GTP. Then, the activated G protein activates the adenylyl cyclase (AC), which in turn catalyzes the production of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). Following an increase in cAMP levels, some proteins are activated, including protein kinase A (PKA), the Exchange Protein Activated by cAMP (EPAC), the Popeye Domain Containing (POPDC) protein family, and so on. After activation, these proteins perform a range of functions. They can exert effects on ion channels, such as promoting calcium (Ca<sup>2+</sup>) channel opening and potassium (K+) channel closing, and they will also catalyze the phosphorylation of corresponding downstream proteins, resulting in multiple biological effects. After exposure to GLP-1 and its analogs, GLP-1R undergoes endocytosis and accumulates in the endosomal compartments. Then, the ligand is proteolyzed by endosomal acidification, and the GLP-1R is recycled to the membrane. After these three processes, GLP-1R is desensitized and can be reactivated [<a href="#B35-medicina-61-00017" class="html-bibr">35</a>]. (<b>B</b>) GLP-1 (1-37) is cleaved to produce GLP-1 (7-36), which is the active form of GLP-1. With the action of dipeptidyl peptidase (DPP-4), GLP-1 (7-36) is cleaved to GLP-1 (9-36) and can be further cleaved to GLP-1 (28-36) in response to neutral endopeptidase (NEP). GLP-1 (9-36) and GLP-1 (28-36) are the metabolites of GLP-1, which have a very low affinity for GLP-1R. They can bind to other receptors (which are still unclear), on the one hand, to activate downstream protein kinases, such as MAPK, PI3K, etc., and on the other hand, to be internalized and cleaved to many small peptides which can affect mitochondrial function. GLP-1R is not involved in these processes [<a href="#B24-medicina-61-00017" class="html-bibr">24</a>,<a href="#B31-medicina-61-00017" class="html-bibr">31</a>]. (<b>C</b>) In addition to GLP-1R, GLP-1R agonists may also bind to some receptors which share homology with GLP-1R, such as the glucagon receptor superfamily, insulin receptor, glucose-dependent insulinotropic peptide (GIP) receptor, insulin-like growth factor 1 (IGR-1) receptor, and so on. After binding GLP-1R agonists to these receptors, downstream protein kinases such as MAPK, PI3K, etc., are activated, and this effect is not blocked by exendin 9-39, which is a GLP-1R antagonist [<a href="#B24-medicina-61-00017" class="html-bibr">24</a>]. (<b>D</b>) Peripheral GLP-1R agonists can interact with sensory afferent neurons, through which nerve impulses are transmitted to the nucleus tractus solitaries (NTS) and activate neurons in it, and then upward to the hypothalamus. After the information is integrated, the hypothalamus sends out descending impulses, which may activate the vagal motor neurons. The activated vagal motor neurons can send stimulatory or inhibitory impulses to various organs, thereby regulating organ function. For example, they can promote pancreatic secretory function and inhibit gastrointestinal motility and gastrin release. These effects, which involve afferent vagus signaling, are not blocked by exendin 9-39 [<a href="#B25-medicina-61-00017" class="html-bibr">25</a>]. This figure was created at <a href="https://BioRender.com" target="_blank">https://BioRender.com</a>.</p> Full article ">Figure 2
<p>Beneficial effects of GLP-1 receptor agonists on PCOS (created in <a href="https://BioRender.com" target="_blank">https://BioRender.com</a>).</p> Full article ">Figure 3
<p>Biological effects of GLP-1 receptor agonists (created in <a href="https://BioRender.com" target="_blank">https://BioRender.com</a>). ↓ indicates the ability to alleviate disease damage or exert an inhibitory effect; ↑ indicates the ability to promote disease progression or exert a stimulatory effect.</p> Full article ">
Open AccessArticle
The Potential of SHAP and Machine Learning for Personalized Explanations of Influencing Factors in Myopic Treatment for Children
by
Jun-Wei Chen, Hsin-An Chen, Tzu-Chi Liu, Tzu-En Wu and Chi-Jie Lu
Medicina 2025, 61(1), 16; https://doi.org/10.3390/medicina61010016 - 26 Dec 2024
Abstract
Background and Objectives: The rising prevalence of myopia is a significant global health concern. Atropine eye drops are commonly used to slow myopia progression in children, but their long-term use raises concern about intraocular pressure (IOP). This study uses SHapley Additive exPlanations (SHAP)
[...] Read more.
Background and Objectives: The rising prevalence of myopia is a significant global health concern. Atropine eye drops are commonly used to slow myopia progression in children, but their long-term use raises concern about intraocular pressure (IOP). This study uses SHapley Additive exPlanations (SHAP) to improve the interpretability of machine learning (ML) model predicting end IOP, offering clinicians explainable insights for personalized patient management. Materials and Methods: This retrospective study analyzed data from 1191 individual eyes of 639 boys and 552 girls with myopia treated with atropine. The average age of the whole group was 10.6 ± 2.5 years old. The refractive error of spherical equivalent (SE) in myopia degree was base SE at 2.63D and end SE at 3.12D. Data were collected from clinical records, including demographic information, IOP measurements, and atropine treatment details. The patients were divided into two subgroups based on a baseline IOP of 14 mmHg. ML models, including Lasso, CART, XGB, and RF, were developed to predict the end IOP value. Then, the best-performing model was further interpreted using SHAP values. The SHAP module created a personalized and dynamic graphic to illustrate how various factors (e.g., age, sex, cumulative duration, and dosage of atropine treatment) affect the end IOP. Results: RF showed the best performance, with superior error metrics in both subgroups. The interpretation of RF with SHAP revealed that age and the recruitment duration of atropine consistently influenced IOP across subgroups, while other variables had varying effects. SHAP values also offer insights, helping clinicians understand how different factors contribute to predicted IOP value in individual children. Conclusions: SHAP provides an alternative approach to understand the factors affecting IOP in children with myopia treated with atropine. Its enhanced interpretability helps clinicians make informed decisions, improving the safety and efficacy of myopia management. This study demonstrates the potential of combining SHAP with ML models for personalized care in ophthalmology.
Full article
(This article belongs to the Special Issue Ophthalmology: New Diagnostic and Treatment Approaches)
►▼
Show Figures
Figure 1
Figure 1
<p>Data preprocessing workflow.</p> Full article ">Figure 2
<p>Modeling scheme.</p> Full article ">Figure 3
<p>SHAP summary and feature importance plot of each base IOP subgroup. (<b>a</b>) SHAP summary plot of base IOP <math display="inline"><semantics> <mrow> <mo>≤</mo> <mn>14</mn> </mrow> </semantics></math> subgroup. (<b>b</b>) SHAP feature importance plot of base IOP <math display="inline"><semantics> <mrow> <mo>≤</mo> <mn>14</mn> </mrow> </semantics></math> subgroup. (<b>c</b>) SHAP summary plot of base IOP <math display="inline"><semantics> <mrow> <mo>></mo> <mn>14</mn> </mrow> </semantics></math> subgroup. (<b>d</b>) SHAP feature importance plot of base IOP <math display="inline"><semantics> <mrow> <mo>></mo> <mn>14</mn> </mrow> </semantics></math> subgroup.</p> Full article ">Figure 4
<p>Three examples of individual case (panels (<b>a</b>–<b>c</b>)) explanations in base IOP <math display="inline"><semantics> <mrow> <mo>≤</mo> <mn>14</mn> </mrow> </semantics></math> subgroup. <math display="inline"><semantics> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </semantics></math>: model prediction outcome. <math display="inline"><semantics> <mrow> <mi>E</mi> <mfenced open="[" close="]" separators="|"> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </mfenced> </mrow> </semantics></math>: expected value.</p> Full article ">Figure 5
<p>Three examples of individual case (panels (<b>a</b>–<b>c</b>)) explanations in base IOP <math display="inline"><semantics> <mrow> <mo>></mo> <mn>14</mn> </mrow> </semantics></math> subgroup. <math display="inline"><semantics> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </semantics></math>: model prediction outcome. <math display="inline"><semantics> <mrow> <mi>E</mi> <mfenced open="[" close="]" separators="|"> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </mfenced> </mrow> </semantics></math>: expected value.</p> Full article ">
<p>Data preprocessing workflow.</p> Full article ">Figure 2
<p>Modeling scheme.</p> Full article ">Figure 3
<p>SHAP summary and feature importance plot of each base IOP subgroup. (<b>a</b>) SHAP summary plot of base IOP <math display="inline"><semantics> <mrow> <mo>≤</mo> <mn>14</mn> </mrow> </semantics></math> subgroup. (<b>b</b>) SHAP feature importance plot of base IOP <math display="inline"><semantics> <mrow> <mo>≤</mo> <mn>14</mn> </mrow> </semantics></math> subgroup. (<b>c</b>) SHAP summary plot of base IOP <math display="inline"><semantics> <mrow> <mo>></mo> <mn>14</mn> </mrow> </semantics></math> subgroup. (<b>d</b>) SHAP feature importance plot of base IOP <math display="inline"><semantics> <mrow> <mo>></mo> <mn>14</mn> </mrow> </semantics></math> subgroup.</p> Full article ">Figure 4
<p>Three examples of individual case (panels (<b>a</b>–<b>c</b>)) explanations in base IOP <math display="inline"><semantics> <mrow> <mo>≤</mo> <mn>14</mn> </mrow> </semantics></math> subgroup. <math display="inline"><semantics> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </semantics></math>: model prediction outcome. <math display="inline"><semantics> <mrow> <mi>E</mi> <mfenced open="[" close="]" separators="|"> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </mfenced> </mrow> </semantics></math>: expected value.</p> Full article ">Figure 5
<p>Three examples of individual case (panels (<b>a</b>–<b>c</b>)) explanations in base IOP <math display="inline"><semantics> <mrow> <mo>></mo> <mn>14</mn> </mrow> </semantics></math> subgroup. <math display="inline"><semantics> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </semantics></math>: model prediction outcome. <math display="inline"><semantics> <mrow> <mi>E</mi> <mfenced open="[" close="]" separators="|"> <mrow> <mi>f</mi> <mfenced separators="|"> <mrow> <mi>x</mi> </mrow> </mfenced> </mrow> </mfenced> </mrow> </semantics></math>: expected value.</p> Full article ">
Open AccessArticle
Role of Ultrasonography in Monitoring Chemotherapeutic Effects on Primary Thyroid Lymphoma: A Single-Center Retrospective Study
by
Shirong Liu, Ying Fu, Ligang Cui, Shumin Wang and Shi Tan
Medicina 2025, 61(1), 15; https://doi.org/10.3390/medicina61010015 - 26 Dec 2024
Abstract
Background and Objectives: In this study, we assessed the utility of ultrasonography in monitoring the chemotherapeutic effects on primary thyroid lymphoma (PTL). Materials and Methods: This retrospective analysis included 17 patients with PTL who received chemotherapy from 2012 to 2022. The sonographic features
[...] Read more.
Background and Objectives: In this study, we assessed the utility of ultrasonography in monitoring the chemotherapeutic effects on primary thyroid lymphoma (PTL). Materials and Methods: This retrospective analysis included 17 patients with PTL who received chemotherapy from 2012 to 2022. The sonographic features were examined pre- and post-treatment using ultrasound (US) to monitor the treatment response at the first to second, third to fourth, and end cycles of chemotherapy and follow-up, and progression-free survival (PFS) and overall survival (OS) were analyzed. Results: The sonographic findings for all the patients indicated diffuse or nodular infiltration with markedly hypoechoic masses, and “stripe-shaped” high echoes and posterior acoustic enhancement were observed. Following one to two cycles of chemotherapy, a US examination revealed varying tumor reduction degrees and diminished blood flow signals. After three to four cycles of chemotherapy, the US demonstrated an evaluation efficacy comparable to that of PET-CT in cases in which the lesion had entirely disappeared postchemotherapy; however, its ability to differentiate between treatment response and residual lesions was less effective compared to that of PET-CT. After the end cycle of chemotherapy, the lesion sizes had significantly decreased compared to those at the baseline (p < 0.05). Postchemotherapy, Adler’s blood flow grades decreased significantly, with 80% graded as 0–1. Among the 10 patients with cervical lymph node enlargement, 70% showed reduced lesion sizes and blood flow signals. The cumulative 5-year PFS and OS rates were both 80% for the diffuse type and 82.5% and 78.8% for the nodular type, respectively (p > 0.05). Conclusions: US can be utilized to monitor the therapeutic response following chemotherapy for PTL, especially for early assessment and repeated dynamic monitoring, and can serve as a complementary follow-up method to PET-CT.
Full article
(This article belongs to the Section Endocrinology)
►▼
Show Figures
Figure 1
Figure 1
<p>An elderly woman with diffuse--type PTL (DLBCL subtype) in the LT who underwent a right thyroidectomy 17 years ago due to Hashimoto’s thyroiditis. Regular follow-ups with ultrasound indicated a significant enlargement of the LT. (<b>a</b>,<b>b</b>) Gray-scale ultrasound of the transverse and longitudinal sections before chemotherapy shows a markedly increased LT volume, with a maximum thickness of 3.6 cm and internal “stripe-shaped” high echoes (arrows). (<b>c</b>) CDU showing abundant blood flow signals. (<b>d</b>) PET-CT before chemotherapy showing significant enlargement of the LT and an abnormal radiation uptake increase (arrows), with an SUVmax of 25.9. (<b>e</b>–<b>g</b>) After two cycles of the R-CHOP regimen, the LT thickness significantly decreased to 1.7 cm, and the parenchymal echo increased but still showed rich blood flow signals. Considering the treatment’s effectiveness, continuing the original chemotherapy regimen was recommended. (<b>h</b>,<b>i</b>) After four cycles of chemotherapy, the ultrasound showed a normal thyroid thickness, an increased glandular echo, which had returned to normal, the disappearance of the lesion, and a decreased blood flow signal. (<b>j</b>) PET-CT confirmed no metabolic increase in the lesion, with an SUVmax of 2.0 (arrows). PTL, primary thyroid lymphoma; DLBCL, diffuse large B-cell lymphoma; LT, left lobe; CDU, color Doppler ultrasound; PET-CT, positron emission tomography-computed tomography; SUVmax, maximum standardized uptake value; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.</p> Full article ">
<p>An elderly woman with diffuse--type PTL (DLBCL subtype) in the LT who underwent a right thyroidectomy 17 years ago due to Hashimoto’s thyroiditis. Regular follow-ups with ultrasound indicated a significant enlargement of the LT. (<b>a</b>,<b>b</b>) Gray-scale ultrasound of the transverse and longitudinal sections before chemotherapy shows a markedly increased LT volume, with a maximum thickness of 3.6 cm and internal “stripe-shaped” high echoes (arrows). (<b>c</b>) CDU showing abundant blood flow signals. (<b>d</b>) PET-CT before chemotherapy showing significant enlargement of the LT and an abnormal radiation uptake increase (arrows), with an SUVmax of 25.9. (<b>e</b>–<b>g</b>) After two cycles of the R-CHOP regimen, the LT thickness significantly decreased to 1.7 cm, and the parenchymal echo increased but still showed rich blood flow signals. Considering the treatment’s effectiveness, continuing the original chemotherapy regimen was recommended. (<b>h</b>,<b>i</b>) After four cycles of chemotherapy, the ultrasound showed a normal thyroid thickness, an increased glandular echo, which had returned to normal, the disappearance of the lesion, and a decreased blood flow signal. (<b>j</b>) PET-CT confirmed no metabolic increase in the lesion, with an SUVmax of 2.0 (arrows). PTL, primary thyroid lymphoma; DLBCL, diffuse large B-cell lymphoma; LT, left lobe; CDU, color Doppler ultrasound; PET-CT, positron emission tomography-computed tomography; SUVmax, maximum standardized uptake value; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.</p> Full article ">
Open AccessReview
Integrated Insights into Metabolic and Bariatric Surgery: Improving Life Quality and Reducing Mortality in Obesity
by
Ruxandra-Cristina Marin, Andrei-Flavius Radu, Paul Andrei Negru, Ada Radu, Denisa Negru, Raluca Anca Corb Aron, Teodora Maria Bodog, Ruxandra Florina Bodog, Paula Bianca Maghiar and Roxana Brata
Medicina 2025, 61(1), 14; https://doi.org/10.3390/medicina61010014 - 26 Dec 2024
Abstract
►▼
Show Figures
Metabolic and bariatric surgery (MBS) is an effective intervention for patients with severe obesity and metabolic comorbidities, particularly when non-surgical weight loss methods prove insufficient. MBS has shown significant potential for improving quality of life and metabolic health outcomes in individuals with obesity,
[...] Read more.
Metabolic and bariatric surgery (MBS) is an effective intervention for patients with severe obesity and metabolic comorbidities, particularly when non-surgical weight loss methods prove insufficient. MBS has shown significant potential for improving quality of life and metabolic health outcomes in individuals with obesity, yet it carries inherent risks. Although these procedures offer a multifaceted approach to obesity treatment and its clinical advantages are well-documented, the limited understanding of its long-term outcomes and the role of multidisciplinary care pose challenges. With an emphasis on quality-of-life enhancements and the handling of postoperative difficulties, the present narrative review seeks to compile the most recent findings on MBS while emphasizing the value of an integrated approach to maximize patient outcomes. Effective MBS and patients’ management require a collaborative team approach, involving surgeons, dietitians, psychologists, pharmacists, and other healthcare providers to address not only physiological but also psychosocial patient needs. Comparative studies demonstrate the efficacy of various MBS methods, including Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy that may considerably decrease morbidity and mortality in individuals with obesity. Future studies should target long-term patient treatment, and decision making should be aided by knowledge of obesity, comorbidity recurrence rates, and permanence of benefits.
Full article
Figure 1
Figure 1
<p>Algorithm of the selection methodology for the bibliographical sources evaluated and cited in this paper.</p> Full article ">Figure 2
<p>Schematic description of the three most commonly used bariatric procedures. LSG, laparascopic sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; OAGB, one anastomosis gastric bypass.</p> Full article ">Figure 3
<p>Organ systems targeted by MBS and the associated physiologic changes.</p> Full article ">Figure 4
<p>Risks and benefits of MBS.</p> Full article ">
<p>Algorithm of the selection methodology for the bibliographical sources evaluated and cited in this paper.</p> Full article ">Figure 2
<p>Schematic description of the three most commonly used bariatric procedures. LSG, laparascopic sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; OAGB, one anastomosis gastric bypass.</p> Full article ">Figure 3
<p>Organ systems targeted by MBS and the associated physiologic changes.</p> Full article ">Figure 4
<p>Risks and benefits of MBS.</p> Full article ">
Open AccessArticle
Using the Cardiac–Electrophysiological Balance Index to Predict Arrhythmia Risk After Colonoscopy
by
Seyit Ali Volkan Polatkan, Seyda Gunay-Polatkan, Ozgen Isik and Deniz Sigirli
Medicina 2025, 61(1), 13; https://doi.org/10.3390/medicina61010013 - 26 Dec 2024
Abstract
Background and Objectives: Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., and colonoscopy is a critical tool for colon cancer screening and diagnosis. Electrolyte disturbances and autonomic nervous system dysfunction that may occur due to bowel preparation and
[...] Read more.
Background and Objectives: Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., and colonoscopy is a critical tool for colon cancer screening and diagnosis. Electrolyte disturbances and autonomic nervous system dysfunction that may occur due to bowel preparation and the colonoscopy procedure itself may play a role in the development of cardiac arrhythmia. This study aimed to assess the index of cardiac–electrophysiological balance (iCEB) to predict ventricular arrhythmia risk related to colonoscopy. Materials and Methods: Patients undergoing elective colonoscopy with a normal sinus rhythm were included. Electrocardiography (ECG) recordings both before bowel preparation and after the colonoscopy procedure were obtained. Values of the index of cardiac–electrophysiological balance (iCEB) were compared. Results: Among 36 patients, it was determined that the heart rate values of the patients before bowel preparation were higher than the heart rate values after colonoscopy [74.5 (60–108) bpm vs. 68.5 (53–108) bpm, p = 0.021]. The duration of QT interval increased (370.9 ± 27.8 ms vs. 398.7 ± 29.4 ms, p < 0.001) and the iCEB increased from 4.1 ± 0.5 to 4.5 ± 0.6 (p < 0.001), indicating a significant post-procedural risk of ventricular arrhythmias. Conclusions: These findings suggest that routine iCEB assessment post-colonoscopy could identify high-risk patients requiring closer monitoring.
Full article
(This article belongs to the Section Gastroenterology & Hepatology)
►▼
Show Figures
Figure 1
Open AccessArticle
Evolution of Liver Resection for Hepatocellular Carcinoma: Change Point Analysis of Textbook Outcome over Twenty Years
by
Yeshong Park, Ho-Seong Han, Seung Yeon Lim, Hyelim Joo, Jinju Kim, MeeYoung Kang, Boram Lee, Hae Won Lee, Yoo-Seok Yoon and Jai Young Cho
Medicina 2025, 61(1), 12; https://doi.org/10.3390/medicina61010012 - 26 Dec 2024
Abstract
Background and Objectives: The aim of this study was to comprehensively analyze the evolution in textbook outcome (TO) achievement after liver resection for hepatocellular carcinoma (HCC) over two decades at a single tertiary referral center. Materials and Methods: All consecutive liver
[...] Read more.
Background and Objectives: The aim of this study was to comprehensively analyze the evolution in textbook outcome (TO) achievement after liver resection for hepatocellular carcinoma (HCC) over two decades at a single tertiary referral center. Materials and Methods: All consecutive liver resections for HCC at Seoul National University Bundang Hospital from 2003 to 2022 were analyzed. The included 1334 patients were divided into four groups by time intervals identified through change point analysis. TO was defined as no intraoperative transfusions, positive margins, major complications, 30-day readmission or mortality, and prolonged length of hospital stay (LOS). Results: Multiple change point analysis identified three change points (2006, 2012, 2017), and patients were divided into four groups. More recent time interval groups were associated with older age (59 vs. 59 vs. 61 vs. 63 years, p < 0.0001) and more comorbidities. Minimally invasive procedures were increasingly performed (open/laparoscopic/robotic 37.0%/63.0%/0%) vs. 43.8%/56.2%/0% vs. 17.1%/82.4%/0.5% vs. 22.9%/75.9%/1.2%, p < 0.0001). TO achievement improved over time (1.9% vs. 18.5% vs. 47.7% vs. 62.5%, p < 0.0001), and LOS was the greatest limiting factor. Conclusions: TO after liver resection improved with advances in minimally invasive techniques and parenchymal sparing procedures, even in older patients with more comorbidities and advanced tumors.
Full article
(This article belongs to the Special Issue Advances in Liver Surgery)
►▼
Show Figures
Figure 1
Figure 1
<p>Multiple change point analysis was performed to identify distinct change points in textbook outcome achievement. (<b>A</b>) Comparison of Bayesian Information Criterion (BIC) values for different numbers of change points revealed that three change points were optimal. (<b>B</b>) The number of breakpoints was confirmed as statistically significant based on ordinary least-squares-based cumulative sum test. (<b>C</b>) Three change points were identified at year 2006, 2012, and 2017.</p> Full article ">Figure 2
<p>Trends in number of annual operations during each time interval.</p> Full article ">Figure 3
<p>Achievement of overall textbook outcome and its individual components over time.</p> Full article ">
<p>Multiple change point analysis was performed to identify distinct change points in textbook outcome achievement. (<b>A</b>) Comparison of Bayesian Information Criterion (BIC) values for different numbers of change points revealed that three change points were optimal. (<b>B</b>) The number of breakpoints was confirmed as statistically significant based on ordinary least-squares-based cumulative sum test. (<b>C</b>) Three change points were identified at year 2006, 2012, and 2017.</p> Full article ">Figure 2
<p>Trends in number of annual operations during each time interval.</p> Full article ">Figure 3
<p>Achievement of overall textbook outcome and its individual components over time.</p> Full article ">
Open AccessArticle
Effects of a Serratus Anterior Plane Block After Video-Assisted Lung Wedge Resection: A Single-Center, Prospective, and Randomized Controlled Trial
by
Seokjin Lee, Tae-Yun Sung, Choon-Kyu Cho, Gyuwon Lee and Woojin Kwon
Medicina 2025, 61(1), 11; https://doi.org/10.3390/medicina61010011 - 26 Dec 2024
Abstract
Background and Objectives: Video-assisted thoracoscopic surgery (VATS) is associated with less postoperative pain than traditional open thoracotomy. However, trocar and chest tube placement may damage the intercostal nerves, causing significant discomfort. An ultrasound-guided serratus anterior plane block (SAPB) is a promising mode
[...] Read more.
Background and Objectives: Video-assisted thoracoscopic surgery (VATS) is associated with less postoperative pain than traditional open thoracotomy. However, trocar and chest tube placement may damage the intercostal nerves, causing significant discomfort. An ultrasound-guided serratus anterior plane block (SAPB) is a promising mode of pain management; this reduces the need for opioids and the associated side-effects. This study evaluated whether SAPB, compared to intravenous analgesia alone, reduces opioid consumption after thoracoscopic lung wedge resection. Materials and Methods: In total, 22 patients undergoing VATS lung wedge resections were randomized into two groups (SAPB and control): both received intravenous patient-controlled analgesia (PCA), and one group received additional SAPB. The primary outcome was the cumulative intravenous fentanyl consumption at 8 h postoperatively. The visual analog scale (VAS) pain scores and the incidence of postoperative complications were assessed over 48 h post surgery. Results: Fentanyl consumption by 8 h post surgery was significantly lower in the SAPB group than in the control group (183 ± 107 μg vs. 347 ± 202 μg, p = 0.035). Although the VAS scores decreased with time in both groups, the differences were not statistically significant. The SAPB group required fewer opioids by 48 h. No significant between-group differences were observed in postoperative complications, including nausea and vomiting. Conclusions: SAPB effectively reduced opioid consumption after VATS lung wedge resection. SABP may serve as a valuable component of multimodal pain management.
Full article
(This article belongs to the Special Issue Current Therapies for Trauma and Surgical Critical Care)
►▼
Show Figures
Figure 1
Open AccessArticle
Predictive Factors Associated with Inappropriate Intravenous Proton Pump Inhibitors Use in Hospitalized Patients: A Case-Control Study
by
Niveen Khoury, David Stepensky, Naim Abu Freha, Mahmud Mahamid, Tawfik Khoury and Amir Mari
Medicina 2025, 61(1), 10; https://doi.org/10.3390/medicina61010010 - 25 Dec 2024
Abstract
Background and Objectives: Proton Pump Inhibitors (PPIs) are the most effective agents for treating acid-related gastrointestinal disorders. The prescription of an intravenous (IV) formulation of PPIs has increased dramatically. The aims of this study were to assess the appropriateness of IV PPI
[...] Read more.
Background and Objectives: Proton Pump Inhibitors (PPIs) are the most effective agents for treating acid-related gastrointestinal disorders. The prescription of an intravenous (IV) formulation of PPIs has increased dramatically. The aims of this study were to assess the appropriateness of IV PPI use and to define the risk factors and outcomes associated with its inappropriate use. Materials and Methods: A case-control retrospective study included all the hospitalized patients who received IV PPIs was conducted. Patient health records were reviewed, data were collected covering the period of the individual patients’ admission to the hospital until discharge or death, and over the 3-month post-discharge period. The appropriateness of the IV PPI use and the resulting clinical outcomes were analyzed. Results: Overall, 540 patients were analyzed. Among them, 130/540 (24%) had inappropriate PPI use in terms of indication, dosage, and duration of treatment vs. 410 patients who had appropriate indications. Two parameters were associated with inappropriate use: congestive heart failure (OR 1.77; p = 0.02) and prescription of IV PPIs by surgeons vs. internists (OR 1.53; p = 0.05). Conclusions: Inappropriate IV PPI use is still common in daily clinical practice. Significant predictors of inappropriate use were the presence of congestive heart failure, elderly age, current use of anticoagulants and antithromotics, and the cases managed by surgeons, naturally due to suspected upper gastrointestinal bleedings.
Full article
(This article belongs to the Special Issue Management of Gastrointestinal Disorders Related to Infectious Diseases and Medications)
►▼
Show Figures
Figure 1
Open AccessArticle
Accessibility and Quality of Palliative Care—Experience in Primary Health Care
by
Viljaras Reigas and Ingrida Šukienė
Medicina 2025, 61(1), 9; https://doi.org/10.3390/medicina61010009 - 25 Dec 2024
Abstract
Background and Objectives: Palliative care is a very important part of medicine, aimed at ensuring an improvement in quality of life and a reduction in distressing symptoms in patients with serious, incurable, progressive diseases. The issues of the accessibility and quality of these
[...] Read more.
Background and Objectives: Palliative care is a very important part of medicine, aimed at ensuring an improvement in quality of life and a reduction in distressing symptoms in patients with serious, incurable, progressive diseases. The issues of the accessibility and quality of these services should be a focus for health policymakers and researchers, although it is acknowledged that a significant portion of the public has not heard about this service. For this reason, it is important to investigate the experience of the accessibility and quality of palliative care services in primary healthcare facilities. Materials and Methods: A quantitative study was conducted in institutions providing outpatient and inpatient palliative care services. A total of 784 patients and 219 family members participated in the study. Participants expressed their opinions through a questionnaire containing 24 statements, to which they responded by indicating their level of agreement on a Likert scale. The collected data were analyzed using statistical analysis software. Results: Palliative care services are widely available in large cities, but their accessibility is very limited in small towns and rural areas. Patients and their families are not familiar with the concept of palliative care, often equating it with the provision of treatment and nursing services, and they see the support of clergy as unnecessary. Although patients and their families rate the quality of the services received positively, they note shortcomings related to communication among staff. Conclusions: Palliative care services are provided within the primary healthcare system by specialists with qualifications regulated by legislation; however, patients do not see the need to receive assistance from clergy members. Based on the study results, it can be concluded that in Lithuania, the accessibility of palliative care is ensured in larger cities but is insufficient in smaller towns and rural areas. Patients tend to rate indicators reflecting the quality of palliative care services positively; however, they are not convinced that these services improve their quality of life.
Full article
(This article belongs to the Section Oncology)
►▼
Show Figures
Figure 1
Figure 1
<p>Concentration of institutions providing palliative care services in the territory of the Republic of Lithuania. Source: prepared by the author based on data from the State Health Insurance Fund (2024).</p> Full article ">Figure 2
<p>Distribution of institutions providing palliative care services according to the operational zones of the territorial health insurance funds (the specified number of organizations). Source: compiled by the author based on data from the State Health Insurance Fund (2024).</p> Full article ">Figure 3
<p>The understanding of palliative care is expressed by patients and their relatives (the mean rating is indicated).</p> Full article ">Figure 4
<p>Patients’ opinions on factors influencing their perception of the quality of palliative care. (the mean rating is indicated).</p> Full article ">Figure 5
<p>Quality elements of palliative care (the mean rating is indicated).</p> Full article ">
<p>Concentration of institutions providing palliative care services in the territory of the Republic of Lithuania. Source: prepared by the author based on data from the State Health Insurance Fund (2024).</p> Full article ">Figure 2
<p>Distribution of institutions providing palliative care services according to the operational zones of the territorial health insurance funds (the specified number of organizations). Source: compiled by the author based on data from the State Health Insurance Fund (2024).</p> Full article ">Figure 3
<p>The understanding of palliative care is expressed by patients and their relatives (the mean rating is indicated).</p> Full article ">Figure 4
<p>Patients’ opinions on factors influencing their perception of the quality of palliative care. (the mean rating is indicated).</p> Full article ">Figure 5
<p>Quality elements of palliative care (the mean rating is indicated).</p> Full article ">
Journal Menu
► ▼ Journal Menu-
- Medicina Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserHighly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Applied Sciences, Dentistry Journal, JCM, JFB, Medicina
Diagnosis and Treatment of Dental Diseases and Tempromandibular Joints
Topic Editors: Rafał Obuchowicz, Małgorzata Pihut, Karolina Nurzynska, Andrzej UrbanikDeadline: 31 December 2024
Topic in
Diagnostics, Healthcare, JCM, JFMK, Medicina, Therapeutics
New Advances in Musculoskeletal Disorders
Topic Editors: Dohyung Kee, Inseok LeeDeadline: 10 January 2025
Topic in
Antibiotics, Applied Microbiology, Immuno, Medicina, Toxins
Bacterial Porins and Their Implication in Pathophysiology of Septic Complications In Vitro and In Vivo
Topic Editors: Pierpaolo Di Micco, Alessandro Perrella, Olga ScudieroDeadline: 31 January 2025
Topic in
Healthcare, JCM, JPM, Medicina
New Advances in Physical Therapy and Occupational Therapy
Topic Editors: Hwi-Young Cho, Ki-Hun Cho, Suk-Chan Hahm, Hye-Rim SuhDeadline: 10 February 2025
Conferences
Special Issues
Special Issue in
Medicina
Latest Advances in Asthma and COPD
Guest Editors: Stefania Principe, Nicola ScichiloneDeadline: 30 December 2024
Special Issue in
Medicina
Opportunities and Challenges for Treating Pancreatic Cancer
Guest Editor: Hassan Mubarak IshqiDeadline: 30 December 2024
Special Issue in
Medicina
Clinical Outcomes and Therapeutic Strategies of Hodgkin Lymphoma
Guest Editor: Vibor MilunovićDeadline: 31 December 2024
Special Issue in
Medicina
Public Health in the Post-pandemic Era
Guest Editor: Elpidoforos SoteriadesDeadline: 31 December 2024
Topical Collections
Topical Collection in
Medicina
Advances in Cornea, Cataract, and Refractive Surgery
Collection Editor: Ivo Guber
Topical Collection in
Medicina
Interventional Oncology
Collection Editors: François Cornelis, Matthias Barral, Adrian Kastler, Dimitrios Filippiadis
Topical Collection in
Medicina
The Utility of Biomarkers in Disease Management Approach
Collection Editors: Salvatore Di Somma, David Brenner
Topical Collection in
Medicina
Pain, Bleeding, Trauma and Infections: The 4 Horsemen of the Apocalypse for the Emergency Medicine
Collection Editor: Marcello Candelli